Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
22.50
+1.10 (5.14%)
At close: May 1, 2024, 4:00 PM
23.24
+0.74 (3.29%)
Pre-market: May 2, 2024, 4:31 AM EDT

Intellia Therapeutics Revenue

In the year 2023, Intellia Therapeutics had annual revenue of $36.28M, a decrease of -30.40%. Revenue in the quarter ending December 31, 2023 was $-1.92M, a -114.12% decrease year-over-year.

Revenue (ttm)
$36.28M
Revenue Growth
-30.40%
P/S Ratio
59.82
Revenue / Employee
$68,964
Employees
526
Market Cap
2.17B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202336.28M-15.85M-30.40%
Dec 31, 202252.12M19.07M57.69%
Dec 31, 202133.05M-24.94M-43.01%
Dec 31, 202057.99M14.89M34.55%
Dec 31, 201943.10M12.67M41.63%
Dec 31, 201830.43M4.32M16.53%
Dec 31, 201726.12M9.64M58.49%
Dec 31, 201616.48M10.44M172.65%
Dec 31, 20156.04M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Teladoc Health 2.62B
CONMED 1.26B
Amphastar Pharmaceuticals 644.40M
Inari Medical 493.63M
TG Therapeutics 233.66M
Deciphera Pharmaceuticals 163.36M
Kymera Therapeutics 78.59M
Keros Therapeutics 151.00K
Revenue Rankings